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Treatments for chronic hepatitis C has evolved significantly in the past 15 years. The standard of care (SOC) is peginterferon 
alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks in patients infected with HCV genotype 1 or 2/3, respectively. The treatment 
duration can be individualized based on the baseline viral load and the speed of the virologic response during treatment. 
However, current therapies are associated with side effects, complications, and poor patient tolerability. Therefore, there is an 
urgent need to identify better strategies for treating this disease. An improved sustained virologic response (SVR) can be 
achieved with new HCV-specific inhibitors against NS3/4A and NS5B polymerases. Recent trials have found SVR rates in 
patients with HCV genotype 1 infection of 61~68% and 67~75% for combining the SOC with the protease inhibitors telaprevir and 
boceprevir, respectively. Several new HCV-specific inhibitors such as protease inhibitors and nucleoside and non-nucleoside 
polymerase inhibitors as well as non-HCV-specific compounds with anti-HCV activity are currently in clinical evaluation. In this 
review we discuss these new treatments for chronic hepatitis C. (Korean J Hepatol 2010;16:263-277)
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INTRODUCTION
Since the identification and molecular cloning of hepatitis C 
virus (HCV) in the late 1980s, it has been estimated that more 
than 170 million people are infected with the virus. In 
approximately 80% of infections the virus is able to elude the 
body’s immune response and succeeds in establishing a chronic 
infection.
1 The number of individuals infected with HCV 
continues to increase and persistently infected persons are at risk 
of developing cirrhosis and hepatocellular carcinoma. The 
current standard of care for the treatment of HCV infection is a 
combination of pegylated interferon and ribavirin (Peg-IFN/ 
RBV). Because of the adverse effects associated with both 
interferon (IFN) and ribavirin and because Peg-IFN/RBV 
provides only about a 45~50% sustained virological response 
(SVR, undetectable HCV RNA for greater than 24 weeks after 
cessation of therapy) in genotype 1-infected individuals, there is 
a need for more potent anti-HCV compounds with fewer adverse 
effects. We will discuss new therapies for chronic hepatitis C. 
Key features of hepatitis C virus
In recent years there have been significant advances in our 
understanding of the replication of HCV and the role of viral 
non-structural proteins.
2-4 HCV has a single-stranded positive 
sense, 9.6 kb RNA genome that is flanked at each terminus by a 
5’ and 3’ non-translated region (NTR) and contains one long 
open reading frame that encodes a precursor polyprotein of about 
3,000 amino acids (Fig. 1). Translation of the polyprotein is 
directed by the internal ribosome entry site located within the 
5’-NTR. The polyprotein is subsequently processed into both 264  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
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Figure 1. Schematic representation of the hepatitis C virus genome.
structural (core, envelope 1, envelope 2) and non-structural (p7, 
NS2, NS3, NS4A, NS4B,NS5A, NS5B) proteins by cellular and 
viral proteases. Core protein is a highly basic protein that forms 
the nucleocapsid. The envelope proteins E1 and E2 are highly 
glycosylated transmembrane proteins that associate non-co-
valently to form the viral envelope. Protein p7 is a highly 
hydrophobic polypeptide that forms hexamers and has been 
reported to have ion channel activity. NS2 is a cis-acting 
autoprotease that is essential for viral replication. NS2 catalyzes 
the cleavage of the polyprotein precursor at the NS2/NS3 
junction, and also plays an essential role in virus assembly. NS3 
is a bifunctional protein with serine protease activity in the amino 
terminal one-third, which is responsible for cleavage at the 
NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B sites, 
and NTPase/helicase activities in the C-terminal two-thirds of 
the protein. The NS4A polypeptide functions as a co-factor for 
NS3 protease activity. NS4B was demonstrated to induce 
specific cellular membrane changes, creating a membranous web 
that serves as a scaffold for the formation of the viral replication 
complex. NS5A is a phosphoprotein with multiple functions and 
is essential for viral replication and assembly. A potential role in 
modulating the IFN response has also been suggested for 
NS5A.NS5B catalyzes the synthesis of both minus-strand and 
plus-strand RNA. 
Hepatitis C and innate immunity
Increasing evidence suggests that HCV can interfere with 
innate immune activation at multiple levels. First, HCV, through 
its viral proteins, can undermine viral recognition by cleaving 
pivotal adaptor proteins in toll-like receptor (TLR3) and retionic 
acid-inducible gene-I (RIG-I) or melanoma differentiation- 
associated gene 5 (MDA5) signaling. Second, HCV directly or 
indirectly modulates key antigen-presenting functions of various 
dendritic cells (DC), contributing to impaired virus-specific 
T-cell activation. Third, IFN α production by plasmacytoid 
dendritic cells (pDCs), the main cell type producing IFNα, is 
drastically reduced in chronic HCV infection. Fourth, chronic 
HCV infection results in activation of proinflammatory path-
ways and mediators in inflammatory cells that contribute not 
only to aberrant innate-adaptive immune interactions but to 
activation of liver fibrosis and a microenvironment that may 
support cancer formation. Therapeutic strategies to counteract 
innate immune alterations in chronic HCV provide a promising 
target and require further investigation.
5
Future therapies for HCV
Advances have been made in the development of new IFNs, 
specifically targeted therapy against hepatitis C (STAT-C) and 
host cell targets inhibiting HCV replication. This review focuses 
on recent clinical trials in that field. 
1. New interferons
Currently, pegylated interferon  is the mainstay of HCV 
treatment regimens. However, several IFNs are under deve-
lopment and may offer improved responses, more convenient 
dosing regimens and/or improved tolerability. Albinterferon is a 
genetic fusion polypeptide of albumin and interferon alfa-2b 
with a longer half life than pegylated interferons. The phase 2 
study comparing different doses of albinterferon alfa-2b and 
ribavirin with peginterferon alfa-2a and ribavirin indicated 
similar sustained virologic response rates with a better toler-
ability of albinterferon alfa-2b based treatment. Based on the 
encouraging findings from the phase 2 study, the efficacy and 
safety of albinterferon alfa-2b administered every two weeks in 
combination with ribavirin for 48 weeks and 24 weeks in patients 
infected with HCV genotype 1 and 2/3, respectively, was 
investigated in two phase 3, randomized, active controlled, 
multi-center studies.
6,7 Both studies (ACHIEVE-1 and ACHIEVE-2) 
were designed to demonstrate non-inferiority of the albinterferon 
alfa-2b regimes compared with peginterferon alfa-2a. Both 
studies achieved the primary objective. In the intention-to-treat 
population, the sustained virologic response rates in the 
peginterferon alfa-2a, albinterferon alfa-2b 900 µg and albinterferon 
alfa-2b 1,200 µg groups were 51.0%, 48.2%, and 47.3% in 
patients infected with HCV genotype 1 and 84.8%, 79.8%, and 
80.0% in patients infected with HCV genotype 2,3 respectively. 
The overall incidence of adverse events, serious or severe 
adverse events in the phase 3 studies was similar between the two 
treatments, indicating that albinterferon alfa-2b is not better 
tolerated than peginterferon alfa-2a. Locteron is a controlled- Jae Young Jang, et al. New treatments for chronic hepatitis C  265
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Figure 3. Different target regions in the hepatitis C virus genome.
release interferon alfa-2b which is injected every 2 weeks. In a 
short term study controlled release interferon alfa-2b showed less 
flu like symptoms than peginterferon alfa-2b injected every 
week indicating that the controlled-release formulation may 
have a better tolerability. Larger trials powered to examine 
adverse event profiles and antiviral activity are being initiated.
8 
Peginterferon- is a pegylated type III interferon that binds to a 
unique receptor with more limited distribution than the type I 
IFN receptor. In a phase 1 healthy volunteer study, peginterferon-
 was pharmacologically active without flu-like symptoms or 
hematologic side-effects. In a phase 1b study the mean decline of 
HCV-RNA in patients with relapsed HCV genotype 1 infection 
was 1.9-3.6 log10 IU/mL after 4 weeks of retreatment with 
peginterferon-. Peginterferon- is currently being investigated 
in combination with ribavirin.
9 Overall, the new IFNs may 
improve convenience and tolerability of IFN-based therapy. 
However, the current results on viral efficacy indicate that 
response rates will not be dramatically improved by the new 
IFNs. 
2. Specifically targeted therapy against hepatitis 
C virus
The most attractive targets for future anti-HCV agents are 
those that specifically target the viral replication cycle (Fig. 2): 
internal ribosome entry site (IRES) inhibitors, viral protease 
inhibitors and transcription (polymerase) inhibitors and virus 
assembly inhibitors (Fig. 3). IRES inhibitors are RNA structures 
that lead to inhibition of HCV polyprotein translation. It is 
known that translation of HCV RNA is initiated by internal entry 
of ribosomes into the 50 non-coding region or IRES in vitro.
10 
IRES inhibitors include anti-sense oligonucleotides (e.g., ISIS 
14803; Isis Pharmaceuticals, Carlsbad, CA), small interfering 
RNAs (siRNA) and ribozymes. To date, the clinical experience 
with oligonucleotides has been disappointing, due to evidence of 
toxicity
11 and poor antiviral activity. A phase I study with ISIS 
14803 demonstrated HCV reductions in only 3/28 patients 
treated, and further development of this compound is unlikely.
11 
New attempts are underway to find more efficient methods to 
inhibit the IRES. The most promising recent advances have 
come in molecules that target the NS3/4A serine protease and the 
NS5B RNA-dependent RNA polymerase. The structural solution 
of the NS3/4A protease and the HCV NS5B polymerase and the 
development of a (sub)genomic replicon system have enabled 
the development and testing of HCV specific compounds. 
Further attractive targets within the HCV genome for antiviral 
therapy are the envelope proteins which are involved in HCV 
entry and NS5A which is involved in replication and assembly 
and quite possibly in mediating IFN alfa resistance. The clinical 
development of NS3/4A protease inhibitors is currently most 
advanced.
1) Protease Inhibitors
NS3-4A Protease
The HCV RNA genome is translated as a single polyprotein 
precursor that is enzymatically processed by host and viral 
proteases.
12 The N-terminal portion of the polypeptide is 
processed by host cell proteases to generate 3 structural proteins 
(core, the E1 and E2 envelope glycoproteins) and p7 (an integral 
membrane protein whose function has not yet been definitively 
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non-structural (NS) proteins required for viral replication and 
maturation, including NS3, a multifunctional enzyme with an 
N-terminal serine protease domain and a C-terminal RNA 
helicase/NTPase domain. With the addition of the NS4A 
cofactor essential for complete peptidase activity, the hetero-
dimeric NS3-4A protease has substrate specificity distinct from 
that of host cell or other viral proteases. Early in vitro and 
primate studies demonstrated the essential role of the NS3-4A 
protease and highlighted the therapeutic potential of an HCV 
protease inhibitor.
13,14 Chimpanzees inoculated with HCV clones 
with abrogated NS3-4A activity failed to generate productive 
HCV infection, suggesting that this protease is integral to viral 
replication and polypeptide maturation.
14 Furthermore, in vitro 
data have demonstrated that the NS3-4A protease may participate 
in host immune evasion by targeting for degradation several key 
cellular signaling molecules associated with endogenous IFN 
production and responsiveness.
15,16 The NS3-4A protease, 
therefore, may represent a dual therapeutic target by inhibiting 
viral replication and potentially restoring the innate response to 
chronic HCV infection.
Several protease inhibitors were investigated in clinical trials. 
Monotherapy with the protease inhibitors ciluprevir, telaprevir 
and boceprevir was shown to be effective in lowering the viral 
load. The development of ciluprevir was stopped due to 
cardiotoxicity in animal studies. Clinical evaluation of telaprevir 
and boceprevir is most advanced. Both protease inhibitors 
showed a rapid selection of drug resistant HCV strains within 2 
weeks of therapy, indicating that protease inhibitor monotherapy 
will not suffice for treatment of patients with chronic hepatitis C. 
Because peginterferon alfa/ribavirin has a completely different 
mode of action and resistance profile than protease inhibitors and 
are active against protease-resistant variants, the current protease 
inhibitors are being investigated in combination with pegin-
terferon with and without ribavirin.
(1) Telaprevir
The peptidomimetic inhibitor of the NS3/4A serine protease 
telaprevir showed a 3 log10 IU/mL decline of HCV RNA during 
the first 2 days of monotherapy in patients infected with HCV 
genotype 1 and previous non-response to IFN based antiviral 
treatment. However, during 14 days of monotherapy, a contin-
uous decline of HCV RNA was noted in only 7 of 28 patients 
(25%). Using a highly sensitive sequencing method several 
mutations associated with resistance to telaprevir were identi-
fied. Mutations associated with resistance occurred in the NS3 
catalytic domain either as single mutation (V36A/M, T54A, 
R155K/T, A156S/T/V) or as double mutation (at positions 
36+155 or 36+156). Low level resistance mutations (V36A/M, 
T54A, R155K/T, and A156S) and high level resistance mutations 
(A156V/T, 36+155, 36+156) can be distinguished. Combination 
therapy of telaprevir with peginterferon alfa-2a and ribavirin was 
effective in preventing the rapid occurrence of resistance. The 
combination therapy of peginterferon alfa-2a/ribavirin/telaprevir 
was investigated in the PROVE1 and 2 studies.
17,18 Both studies 
are complete and telaprevir is one of the first STAT-C compound 
for which sustained virologic response rates have been reported 
for combination therapy with peginterferon alfa-2a and ribavirin. 
In both trials triple therapy was given for 12 weeks. The 
sustained virologic response rates in PROVE1 and PROVE2 
were 61% and 68% in patients treated with peginterferon 
alfa-2a/ribavirin/telaprevir for 12 weeks followed by peginter-
feron/ribavirin for 36 or 12 weeks, respectively. The sustained 
virologic response rates in these telaprevir arms were sig-
nificantly higher compared with the sustained virologic response 
rates in the standard of care control arms (41% and 46% in 
PROVE1 and PROVE2 respectively). Overall, the PROVE- 
studies confirm that protease inhibitors are able to increase 
sustained virologic response rates in patients with HCV genotype 
1 infection. Furthermore, the PROVE2 study indicates that by 
addition of telaprevir to SOC (the standard of care) higher 
sustained virologic response rates can be achieved with shorter 
treatment duration. The high antiviral efficacy of telaprevir in 
combination with IFN alfa raises the question whether ribavirin 
is still necessary in the era of protease inhibitors and if double 
combination with peginterferon and a protease inhibitor is 
sufficient for a sustained virologic response. In PROVE2 the 
sustained virologic response rate in patients treated with 
telaprevir/peginterferon alfa-2a without ribavirin for 12 weeks 
was lower than in patients treated with telaprevir/peginterferon 
alfa-2a plus ribavirin for 12 weeks (36% vs. 60%). The lower rate 
of sustained virologic response in the group without ribavirin 
was due to a higher relapse rate compared to the groups with 
ribavirin (48% vs. 14-29%). The results of the PROVE2-trial 
provide evidence that ribavirin has additive antiviral activity to 
telaprevir and peginterferon alfa-2a and that triple therapy is 
required for optimal sustained virologic response rates. Tela-
previr in combination with peginterferon alfa-2a and ribavirin 
was also investigated in patients with prior non-response to 
standard of care. The PROVE3 trial was a randomized, placebo- 
controlled phase 2 study assessing safety and efficacy of tela-Jae Young Jang, et al. New treatments for chronic hepatitis C  267
previr plus peginterferon alfa-2a±ribavirin in HCV genotype 1 
patients who previously failed peginterferon/ribavirin treat-
ment.
19 The overall sustained virologic response rates were signi-
ficantly higher in the telaprevir arms (peginterferon alfa-2a/ 
ribavirin/telaprevir for 12 or 24 weeks followed by peginterferon 
alfa-2a/ribavirin for 12 and 24 weeks, respectively) compared 
with the control arm. Superior sustained virologic response rates 
were observed in the triple therapy arms compared with the SOC 
control arm or the peginterferon/telaprevir arm without ribavirin 
(38~39% vs 9~10%). Overall, the study provides evidence that 
protease inhibitors in combination with standard of care will be a 
viable treatment option for patients who failed previous antiviral 
therapy. 
(2) Boceprevir
Boceprevir, another NS3/4A serine protease inhibitor, binds 
reversibly to the NS3 protease active site and has potent activity 
in the replicon system alone
20 and in combination with IFN 
alfa-2b.
20 In a phase 1 open-label combination study, boceprevir 
was evaluated in combination with pegylated interferon-alfa-2b 
versus either agent alone in a crossover design in adult patients 
who have HCV genotype 1 and were previous non-responders to 
pegylated interferon-alfa-2b–based therapy.
21 Patients were 
randomized to receive in random sequence (1) boceprevir (200 
mg or 400 mg every 8 hours) as monotherapy for 7 days, (2) 
pegylated interferon-alfa-2b (1.5 mg/kg/wk) as monotherapy for 
14 days, and (3) boceprevir plus pegylated interferon-alfa-2b 
combination therapy for 14 days in a three-period crossover 
design with a 3-week washout between treatments. Mean 
maximum log10 changes in HCV RNA were -2.45±0.22 and 
-2.88±0.22 for pegylated interferon-alfa-2b plus boceprevir at a 
rate of 200 mg or 400 mg, respectively, compared with -1.08± 
0.22 and -1.61±0.21 for boceprevir at a rate of 200 mg and 400 
mg, respectively, and -1.08±0.22 and -1.26±0.20 for pegylated 
interferon-alfa-2b alone in the groups with boceprevir adm-
inistered at 200 mg and 400 mg, respectively.
21 As for telaprevir 
several mutations associated with resistance were identified 
during boceprevir monotherapy (V36, T54, R155, A156, V170, 
V55A).
22 Boceprevir shows an overlapping resistance profile 
with telaprevir, indicating that a combination therapy of both 
protease inhibitors will not be promising. Recently, the final 
results of the HCV SPRINT-1 study assessing safety and efficacy 
of boceprevir in combination with peginterferon alfa-2b (1.5 μ
g/kg/week) and ribavirin in treatment naïve patients with chronic 
hepatitis C genotype 1 infection were presented.
23 The triple 
combination arms with a total treatment duration of 48 weeks 
with or without a 4 weeks peginterferon-alfa2b/ribavirin lead-in 
were associated with significantly higher sustained virologic 
response rates than the low dose ribavirin arm and the standard of 
care control arm (75% and 67% vs. 36% and 38%, respectively). 
The results from the PROVE and the SPRINT trials confirm the 
concept that specific protease inhibitors are able to improve the 
cure rates of patients with chronic hepatitis C. Furthermore, both 
trials indicate that ribavirin is still necessary for achieving a 
sustained virologic response. 
(3) New protease inhibitors
ITNM-191, SCH 900518, TMC435, BI201335 and MK-7009 
are novel NS3/4A protease inhibitors currently in clinical trials. 
Sustained virologic response rates are not available so far. 
ITMN-191 is a potent HCV NS3/4A protease inhibitor that 
achieves high liver concentrations following oral administr-
ation.
24 ITNM-191 in combination with peginterferon alfa-2a/ 
ribavirin showed a stronger decline of HCV RNA compared with 
peginterferon alfa-2a/ribavirin standard of care after two weeks 
of treatment (4.7-5.7 log10 IU/mL vs 2.0 log10 IU/mL). After 2 
weeks, 13-57% of patients in the triple therapy arm while no 
patient in the standard of care arm showed undetectable HCV 
RNA. SCH 900518 with and without ritonavir boosting showed 
robust reductions in HCV RNA levels in both treatment- 
experienced and naïve HCV genotype 1-infected patients (4.01 
log10 IU/mL and 4.5 log10 IU/mL vs 0.09-0.19 log10 IU/mL after 
8 days in patients treated with SCH 900518 400 mg twice/day 
plus peginterferon alfa-2a/ribavirin plus ritonavir 100 mg/d and 
SCH 900518 800 mg thrice/day plus peginterferon alfa-2a/ 
ribavirin, respectively, vs. patients receiving peginterferon 
alfa-2a/ribavirin alone).
25 TMC435 administered for 4 weeks in 
combination with peginterferon-alfa-2a/ribavirin was well 
tolerated and demonstrated potent antiviral activity in HCV 
genotype 1 infected treatment-experienced patients (4.3-5.3 
log10 IU/mL in the TMC435 arms vs. 1.5 log10 IU/mL in the 
control arms).
26 BI 201335 was investigated as monotherapy for 
14 days and in combination with peginterferon alfa-2a/ribavirin 
for 28 days in experienced patients and showed a median HCV 
RNA decline of 3-4.2 log10 IU/mL in monotherapy and 4.8-5.3 
log10 IU/ml in combination therapy.
27-29 MK-7009 is a non- 
covalent competitive inhibitor of HCV NS3/4A protease. In 
treatment naïve patients MK-7009 was administered for 28 days 
in combination with pegylated interferon-alfa/ribavirin. The 
rapid virologic rate was higher in patients treated with triple 268  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
therapy than in patients treated with standard of care 
(68.8~82.4% vs. 5.6%).
30 All new compounds were relatively 
safe and well tolerated in monotherapy as well in combination 
with standard of care and will be further developed for HCV 
treatment.
2) Polymerase inhibitors
Nucleoside analog versus Non-nucleoside polymerase inhibitors
Viral polymerase inhibitors are currently the largest class of 
antiviral drugs for the treatment of hepatitis B, HIV, and herpes 
viruses, and were some of the first drugs developed for the 
treatment of HCV. A large proportion of these drugs are 
nucleoside analogs, synthetic compounds structurally similar to 
nucleosides, the building blocks of RNA and DNA. The NS5B 
polymerase inhibitors for treatment of chronic hepatitis C are 
consist of 2 classes: (1) nucleoside or nucleotide inhibitors 
(active site inhibitors) and (2) non-nucleotide inhibitors 
(allosteric inhibitors). Nucleoside inhibitors are analogs of 
natural substrates of the polymerase that are incorporated into the 
growing RNA chain leading to chain termination by binding the 
active site of NS5B. They must be phosphorylated before being 
active. Because NS5B is a highly conserved region of the HCV 
genome, nucleoside inhibitors have similar activity against all 
genotypes and high genetic barriers to resistance.
31 In contrast to 
nucleoside inhibitors, non-nucleoside inhibitors achieve NS5B 
inhibition by binding to 1 of the at least 5 allosteric enzyme sites 
resulting in conformational changes of the protein-inhibiting 
catalytic activity of polymerase. They have genotype specific 
activity and potential for rapid selection of resistance. The rapid 
development of resistant mutants is possible with non-nucleoside 
inhibitors because they bind distantly from the active site of 
NS5B and mutations at the non-nucleoside inhibitor binding site 
may not necessarily lead to impairment of enzyme function. 
Due to their distinctive binding sites, different polymerase 
inhibitors could theoretically be used in combination to avoid 
development of resistance.
31 Several HCV NS5B polymerase 
inhibitors have demonstrated clinical efficacy and advanced to 
clinical trials.
(1) Nucleoside analog NS5B Polymerase inhibitors
򰇯Valopicitabine
Valopicitabine (NM203) is the oral prodrug of the nucleoside 
analog 20-C-methyl-cytidine. The maximum effective dose was 
not defined because dosing was limited by the development of 
gastrointestinal side effects. The efficacy and safety of 
valopicitabine alone and in combination with pegylated 
interferon have been assessed in clinical trials.
32 Studies of 
valopicitabine monotherapy indicated that a dose of 400 to 800 
mg was optimal; higher doses were not well tolerated due to 
significant side effects, specially nausea and vomiting. Doses of 
200 mg of valopicitabine were well tolerated in combination 
with peginterferon and effective. Studies in combination with 
ribavirin were not done due to increased gastrointestinal side 
effects. One major phase IIb trial examining the combination of 
valopicitabine with peginterferon failed to demonstrate im-
proved efficacy over the SOC of peginterferon/ribavirin.
32 Side 
effects requiring dose reductions in the higher dose peg-
interferon/valopicitabine arms limited efficacy and tolerability 
of this regimen. On review of the clinical data, the U.S. Food and 
Drug Administration (FDA) revised the clinical trial of treating 
naive patients by reducing the dose of valopicitabine from 800 
mg to 200 or 400 mg/d. Subsequent analysis by the FDA of the 
risk-benefit profile from the phase II clinical trial resulted in 
suspension of clinical development of valopicitabine in the 
United States.
33 Although development of valopicitabine for the 
treatment of chronic hepatitis C in the United States has ceased, 
trials in Europe in combination with peginterferon/ribavirin are 
ongoing. Results of these latter trials will determine the ultimate 
fate of valopicitabine. 
򰇯R1626
R1626 is a tri-isobutyl ester prodrug of the nucleoside analog 
R1479 (40-azidocytidine). It is rapidly converted by esterases in 
gastrointestinal epithelial cells to R1479, whereby it is 
phosphorylated and becomes a potent and highly selective 
terminator of HCV NS5B. R1626 was generally well tolerated up 
to 3,000 mg twice a day with only mild side effects in 67% of 
cases. Gastrointestinal symptoms (diarrhea and nausea) were 
common, especially in the group taking 4,500 mg twice a day. In 
addition, there was pancytopenia suggesting bone marrow 
suppression with a dose of 4,500 mg twice a day. For these 
reasons, future clinical trials were limited to 3,000 mg twice a 
day or less. Sequence analysis of the entire NS5B coding region 
revealed no known R1479 resistance mutations (S96T or 
S96T/N142T) or any other amino acid substitutions compared 
with the baseline sequence. In mid-2008, end-of-treatment 
response (ETR; undetectable HCV RNA at 48 weeks of therapy) 
results were presented from the phase IIa study.
34 Eighty-four 
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SOC achieve ETR compared with 65% receiving SOC. Pockros 
et al. showed virological response rates during and 24 weeks 
after the end of the study (equivalent to SVR).
35 The high rate of 
relapse is likely due to the short period of R1626 dosing (4 
weeks). R1626 has been withdrawn from further consideration 
for future drug development in the treatment of chronic hepatitis 
C. Two major factors led to this decision by the manufacturer: 
suspicion for significant bone marrow suppression with even 
short courses of treatment and lack of superior efficacy with the 
studied regimens, compared with SOC. 
򰇯R7128
R7128, a prodrug of PSI-6130, is an oral cytidine nucleoside 
analog polymerase inhibitor. In dose-response studies, there was 
an increase in virologic response with increasing dose, over a 
dose range from 750 mg daily every day to 1,500 mg twice daily. 
A phase Ib clinical study demonstrated a mean HCV RNA 
reduction of 2.7 log10 IU/mL when administered as monotherapy 
at 1,500 mg twice a day for 2 weeks in treatment experienced 
patients infected with genotype 1.
36 In this study no serious 
adverse events were reported with more adverse events 
occurring in the placebo group. In a phase IIa study, 81 
naive-to-therapy, genotype-1 patients were randomized across 3 
cohorts (cohort 1, R7128 500 mg twice a day 1 peginterferon 1 
ribavirin (SOC); cohort 2, R7128 1,000 mg twice a day 1 SOC; 
and cohort 3, R7128 1,500 mg twice a day 1 SOC; 20–25 
active/5-6 placebo stratification) and treated for 28 Days.
37 
Baseline characteristics were similar in each group. Subjects 
receiving 1,000 mg or 1,500 mg twice a day+SOC achieved a 
rapid virologic response (HCV RNA <15 IU/mL at week 4) in 
88% and 85%, respectively versus 19% for placebo+SOC. No 
apparent differences in HCV RNA reduction across race/ 
ethnicity with respect to R7218 1,000 or 1,500 mg twice a day 
dosing. No dose-related changes in terms of safety and 
tolerability were noted. No serious adverse events were noted 
and most side effects were mild. Preliminary data (up to day 56 in 
all) are available in 25 HCV genotype-2 and -3 patients (10 non- 
responders, 15 relapsers to SOC) receiving R7128 1,500 mg 
twice a day 1 SOC (n=20) compared with placebo 1 SOC (n=5) 
for 28 days.
38 Plasma HCV RNA levels decreased a mean of 5.0 
log10 IU/mL (90% rapid virological response [RVR]) in the 
treatment group compared with 4.3 log10 IU/mL (60% RVR) in 
the placebo group. Again, no serious adverse events or 
dose-related side effects were reported with many side effects 
attributed to peginterferon (fatigue, malaise, and headache). In 
early 2009, Pharmasset announced that they and their developing 
partner, Roche, agreed with the FDA on the final design for a 
phase IIb trial with R7128.
39 This study is anticipated to enroll 
400 treatment naive, genotype-1 or genotype-4 HCV-infected 
patients. The primary efficacy end point will be sustained 
virological response and will involve 5 arms (24 and 48 weeks of 
total treatment, 500 mg and 1,000 mg of R7128 twice a day for 8 
weeks or 12 weeks, and a control arm of pegylated interferon and 
ribavirin for 48 weeks). In November 2008, Pharmasset, Roche, 
and InterMune initiated the INFORM-1 trial to investigate the 
combination of R7128 with InterMune’s protease inhibitor 
(ITMN-191). 
򰇯IDX184
In January 2009, Idenix announced that it will study its 
polymerase inhibitor, IDX184, in HCV genotype-1 treatment- 
naive patients who will receive 1 of 4 doses (25 to 100 mg once a 
day). The study will include 10 patients who will receive the 
study drug and 2 patients who will receive a placebo drug. Unlike 
first-generation HCV nucleoside inhibitors (valopicitabine, 
R7128, and R1626), IDX184 is a ‘‘liver-targeted’’ prodrug, 
which theoretically will provide increased anti-HCV efficacy 
and safety. Preliminary studies in monkeys have shown 95% 
hepatic extraction of orally administered IDX184 with low 
systemic IDX184 and nucleoside metabolite levels.
40 In 
chimpanzees infected with HCV genotype 1, once daily oral 
administration of 10 mg/kg/d of IDX184 produced mean viral 
load reduction of 2.3 log10 after 4 days of dosing.
41
򰇯MK-0608
MK-0608 (Merck) is a potent nucleoside analog in preclinical 
trials.
42
(2) Non-nucleoside analogues
򰇯HCV-796
HCV-796 is a non-nucleoside polymerase inhibitor that has 
demonstrated potent antiviral activity in vitro and in patients with 
chronic hepatitis C. Monotherapy showed a maximum antiviral 
effect after 4 days of treatment with a mean HCV RNA reduction 
of 1.4 log100 IU/mL. During monotherapy HCV-796 resistant 
variants were rapidly selected. HCV-796 resistance was associated 
with the C316Y amino acid substitution. The combination of 
HCV-796 and peginterferon alfa-2b produced a mean viral 
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compared to 1.6 log10 IU/mL with peginterferon alfa-2b alone.
43 
Due to clinically significant elevations of liver enzymes, 
HCV-796 clinical development was discontinued in the phase 2 
program. Recently, data from several new non-nucleoside 
polymerase inhibitors were presented. 
 
򰇯PF 00868554
The development of filibuvir (PF 00868554) is most 
advanced.
44 Filibuvir showed in monotherapy of patients with 
chronic HCV genotype 1 infection a dose-dependent inhibition 
of viral replication, with maximum reductions in HCV RNA 
ranging from 0.97 to 2.13 log10 IU/mL. During monotherapy, 
mutations associated with resistance at position 423 rapidly 
occurred indicating a low resistance barrier of filibuvir. Filibuvir 
is currently investigated in combination with peginterferon 
alfa-2a and ribavirin. In treatment naïve patients with HCV 
genotype 1 infection triple therapy was associated with a rapid 
virologic response rate of 60-75% while no patient in the placebo 
arm achieved a rapid virologic response. The most frequently 
reported adverse events were headache, fatigue, insomnia and 
nausea. 
򰇯VCH-916 
VCH-916 showed a maximum HCV-RNA decline ranging 
between 0.2 and 2.5 log10 IU/mL within 14 days of treatment.
45 
Like HCV-796 and filibuvir HCV variants conferring resistance 
were selected during the course of dosing with VCH-916 over a 
14-day period. Sequencing revealed selection of L419S/M, 
M423T/V/I, I482L and V494A variants during monotherapy 
indicating that VCH-916 should be used in combination to 
maintain viral suppression and prevent emergence of resi-
stance.
46
򰇯ANA598
ANA598 showed a decline of HCVRNA after 3 days of 
monotherapy ranging between 0.4 and 3.4 log10 IU/mL.
47 
ANA598 was combined in vitro with IFN alfa, the HCV NS3/4 
protease inhibitor telaprevir, the NS5B nucleoside polymerase 
inhibitor PSI-6130, and the TLR7 agonist ANA773, respectively. 
The in vitro combination studies demonstrated additive to 
synergistic antiviral effects of ANA598 in combination with 
other anti-HCV agents having distinct mechanisms of action and 
non-overlapping resistance profiles. The study indicates that 
combination therapy may produce a greater viral load reduction 
and potentially delay the emergence of drug resistance in vivo. 
Further studies are planned with ANA598 in combination with 
standard of care.
47
򰇯BI 207127
BI 207127 monotherapy showed an HCV-RNA decline after 5 
days ranging between 0.6 and 3.1 log10 IU/mL in patients with 
chronic hepatitis C genotype 1 infection.
27 Similar to ANA598, 
no increase in HCV RNA levels was observed during short term 
BI 207127 monotherapy. One patient developed a severe 
generalized erythema with facial involvement, which resolved 
within 2 days after discontinuation of BI 207127 and after 
antihistaminic treatment. All other adverse events were rated 
“mild” or “moderate” and were apparently not dose-related. 
Further clinical development of the compound in combination 
therapy is planned. 
򰇯VCH-222
 For VCH-222 only preliminary efficacy results on the first 4 
treatment-naïve patients with chronic HCV genotype 1 infection 
treated for 3 days are available showing a decline of HCV-RNA 
ranging between 3.2 and 4.2 log10 IU/mL.
48
򰇯Others
MK-3281, ABT-072 and ABT-333 are additional non-nucleo-
side polymerase inhibitors in development for which no results 
on antiviral activity in patients with chronic hepatitis C are yet 
available.
49 ABT-072 and ABT-333 were shown to have oral 
bioavailability in rats and dogs, in vitro metabolic stability and 
low potential for drug interactions predicting favorable 
pharmacokinetics in humans.
3) Combination therapy
The nucleoside polymerase inhibitor R7128 and the protease 
inhibitor ITMN-191 showed substantial antiviral activity in 
patients with chronic hepatitis C. The INFORM-1 trial is the first 
trial to investigate the combination of a nucleoside polymerase 
inhibitor and a protease inhibitor in patients with chronic 
hepatitis C.
50 Both compounds have different resistance profiles 
and thus are good candidates for combination therapy. After 14 
days of combination therapy (with yet lower doses for both 
compounds), a decline of HCV-RNA ranging between 2.9 and 
5.0 to log10 IU/mL was observed. One patient had undetectable 
HCV-RNA. No viral rebound was observed, providing encouraging 
evidence that combinations of direct acting antiviral agents could 
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resistance. Higher doses are currently evaluated. An important 
question is whether combination therapy is sufficient for achieving 
a sustained virologic response and what treatment duration 
would be necessary.
3. Host cell targeting inhibitors
A unique aspect of HCV that has not been observed in other 
viruses is that the entire viral life cycle is associated with 
cholesterol metabolism in host cells. Thus, drugs that target 
cholesterol metabolism might be useful for treating HCV 
infection.
51 Also, drugs targeting the host proteins required for 
HCV infection, nuclear receptor or anti-receptor antibodies may 
be more helpful in combating the viral infection.
52 Targeting host 
cofactors of the HCV life cycle by different strategies (inhibition 
of viral entry, targeting host metabolism, nuclear receptors and 
other principles) may be a novel rational option, especially 
because they impose higher genetic barriers for resistance than 
direct antiviral compounds. However, the principle drawback of 
these strategies is the greater potential for cellular toxicity.
1) Inhibition of viral entry
(1) Anti-receptor antibodies
Entry into the host cell is the primary step in the HCV life 
cycle, which makes it an attractive target for antiviral therapies. 
Attachment and cell entry of HCV is pH dependent and is a 
clathrin-dependent endocytic pathway.
53,54 Although the mole-
cular details regarding how this virus enters a cell are unknown, 
CD81
55 and scavenger receptor class B type 1
56 seem to be the 
key receptor components that mediate viral entry. However, 
other potential receptors play a role in entry of HCV such as low 
density lipoprotein (LDL) receptor,
57 negatively charged gly-
cosaminoglycans, and recently, Evans et al.
58 added another 
molecule to the list of HCV receptors, namely, the tight junction 
protein claudin-1 (CLDN1). Targeting viral receptors can be 
accomplished by various methods, including the design of small 
molecules that bind to proteins and prevent interaction(s) with 
HCV. The crystal structure of CD81 long extracellular loop 
enabled the design of small molecules that bind CD81 and 
prevent its association with HCV E2.
59 A recent presentation by 
Liu et al.
60 identified compounds that displayed a dose- 
dependent inhibition of HCV infection. 
(2) Scavenger receptor BI (SR-BI)
Recently, a novel function of SR-Bs for viral antigen uptake 
and recognition has been suggested; SR-BI may represent a 
cell-surface receptor for the recognition of viral antigens and be 
implicated in trafficking exogenous viral antigens toward the 
major histocompatibility complex (MHC) class I presentation 
pathway. The SR-BI viral antigen interaction may represent a 
novel target for therapeutic or preventive strategies aiming at the 
induction of efficient antiviral immune responses
61 as an 
alternative to the development of anti-HCV antibodies, one 
could consider anti-SR-B1 human MAbs or anti-CD-81 capable 
of interfering with HCV infection as potential therapeutic leads. 
Recent data show that BLT-4 and other inhibitors of 
SR-BI-mediated lipid transfer not only inhibit HCV entry but 
also fully restore the potency of neutralizing antibodies in 
infection assays conducted in the presence of HS/HDL, 
indicating an intriguing link between neutralization efficiency 
and stimulation of cell entry.
62,63 However, it is too early to know 
whether the potential for vaccines and passive immunotherapy 
will be realized. Cholesterol-lowering drugs may be beneficial in 
patients with chronic hepatitis C by exerting effects on 
cholesterol metabolism and lipoprotein trafficking via SR-BI.
(3) CD81
Meuleman et al.
52 showed that CD81 is a critical receptor for 
HCV infection in vivo recently. Prophylactic injection of 
monoclonal anti-CD81 antibodies prevented infection of human 
liver-uPA-SCID mice, however once an infection occurred, no 
significant difference in viremia was observed between anti- 
CD81-treated and control animals (irrelevant antibody). These 
results strongly support the use of CD81 as a clinical target for 
HCV prevention, especially in the context of orthotopic liver 
transplantation.
52
2) Targeting host metabolism
HCV seems to be not only an infectious hepatotropic virus but 
also a metabolic disease
64 with a wide area of metabolic 
disarrangement, including lipid metabolism,
65 glucose meta-
bolism
66 and vitamin D metabolism.
67,68
(1) Host lipid biosynthesis inhibitors
Recently, using the new fluxomic techniques, studies revealed 
that viral infection takes control of cellular metabolism and 
drives, among other things, marked increases in fatty acid 
synthesis. Interfering with glucose-to-fatty acid metabolism 
could stop viral replication, because fatty acid biosynthesis is not 
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to the ability of HCV to build their envelopes, reproduce and 
spread. So, targeting of host lipid metabolism by the existing 
anti-obesity drugs may represent a new way to block these 
metabolic changes and inhibit viral replication, and may 
therefore be a potential novel approach that could improve 
response rates to treatment.
69 While statins have shown promise 
in vitro, they do not appear to have antiviral activity in vivo at 
clinically used doses. However, data suggesting synergism with 
α-IFN, support ‘proof-of-concept’ for trials combining fluva-
statin with standard pegylated interferon plus/minus ribavirin. 
Cautious, prospective and randomized trials are needed before 
we can call statin therapy an adjuvant treatment panacea.
69 
Another class of drugs designed for treating hypercholestero-
lemia blocks the assembly and secretion of very low density 
lipoprotein (VLDL). These drugs may also be effective in 
treating HCV infection because they inhibit release of HCV 
particles from infected cells.
70 In this regard, antisense RNA 
drugs targeting apoB
71 and several microsomal triglyceride 
protein (MTP) inhibitors
72,73 have already been tested in clinical 
trials because of their ability to block VLDL secretion, thereby 
lowering the plasma levels of VLDL triglycerides and LDL 
cholesterol. Long-term treatment with MTP inhibitors led to the 
toxic accumulation of fat in livers,
72,73 thus hampering the 
approval of these drugs for the treatment of hypercholesterol-
emia on a long-term basis. However, short-term treatment (up to 
several weeks) reduced the plasma level of VLDL with only 
minor adverse effects, which disappeared after drug discontinua-
tion.
72 It will be interesting to examine whether short-term 
treatment with MTP inhibitors is beneficial in treating HCV 
infection. Of note, the natural flavonoid naringenin, demonstra-
ted an ability to block both VLDL secretion and HCV secretion 
in paralle.
74
(2) Cyclophilin B inhibitors
Another host cell factor involved in HCV RNA replication is 
the human protein cyclophilin B protein which interacts with the 
C-terminal region of NS5B and appears to stimulate its RNA 
binding activity.
75 The cyclophilin B inhibitor Debio-025 
potently suppresses genotype 1 HCV replication in vivo.
76
(3) Insulin resistance
Insulin resistance emerges as a very important host factor in 
patients with CHC, mainly because it has been related to 
steatosis development, fibrosis progression and non-response to 
peg-interferon plus ribavirin.
77 Insulin resistance is the main 
pathogenic factor in the development of steatosis in chronic 
hepatitis C; both viral induced insulin resistance and metabolic 
insulin resistance could be implicated in the development of 
steatosis.
78 Insulin resistance, calculated by the homeostasis 
model assessment (HOMA), has been found to be one of the 
most important host factors related to the impermanence of 
virological response to combined therapy in chronic hepatitis C 
patients.
79 Recently, obesity has been identified as a modifiable 
host factor associated with a lower SVR. An elevated body mass 
index (BMI) is associated with reduced insulin sensitivity and 
HCV treatment outcome. This observation has led experts to 
suggest that managing insulin resistance might improve hepatitis 
treatment outcome and that insulin resistance seems to be a new 
target in the management of hepatitis C. The rationale of 
increasing insulin sensitivity in patients with chronic hepatitis C 
is based on the premise that insulin resistant state directly or 
indirectly inhibits the antiviral action of IFN-α-β, or increases 
the viral fitness making it more resistant to therapy, or both.
80,81 
Intracellular factors dysregulated by HCV and responsible for 
the insulin resistant phenotype may play promiscuous effects as 
they are also involved in regulating IFN-α signaling. These 
factors include some members of the suppressor of cytokine 
signaling (SOCS) family
82-84 and the protein phosphatase 2A.
85 
Thus, modulating the levels and/or the activity of these factors 
may not only reverse hepatic insulin resistance but also help in 
establishing the IFN-α- induced antiviral state at the site of HCV 
replication. This is one of the reasons for trying to restore insulin 
sensitivity in chronic hepatitis C patients, especially those who 
failed to respond to therapy. However, specific inhibitors of 
SOCS family members and of the protein phosphatase 2A are 
either not suitable for in vivo administration or are toxic. 
Alternatively, increasing insulin sensitivity may be achieved by 
modulating serum levels of specific cytokines, such as tumor 
necrosis factor-α (TNF-α), associated with insulin resistance,
86,87 
but the administration of anti-TNF-α antibodies to chronic 
hepatitis C patients may be risky.
88 Recently, metformin-based 
triple therapy has been shown to be safe, improving insulin 
sensitivity and increasing SVR rate by 10% in patients with 
hepatitis C genotype 1 and insulin resistance (HOMA > 2). This 
therapy was especially effective in females in whom metformin 
significantly raised the SVR rate.
89
3) NUCLEAR RECEPTORS
(1) Peroxisome proliferator-activated receptor (PPAR)
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the regulation of glucose homeostasis. In addition to the direct 
effects on factors involved in lipid and glucose homeostasis,
90-94 
PPARs may have insulin sensitizing effects via  their anti- 
inflammatory activity.
95,96 Thus, treatment with PPAR agonists 
results in improved insulin sensitivity via diverse mechanisms, 
both direct and indirect, and both at the level of the liver and at 
the level of extrahepatic tissues.
90 Also, in a recent study, the 
level of PPARα mRNA was found to be profoundly suppressed 
in the liver of chronic hepatitis C patients (about 85% compared 
to control livers).
97 The suppression of PPAR-α leads to the 
upregulation of nuclear factor (NF)-κB. NF-κB has been shown 
to accelerate virus replication,
98 and it has been speculated that 
activation of PPAR-α with subsequent NF-κB suppression leads 
to decreased HCV replication in hepatocytes.
99 Given the 
availability of potent agonists, PPARs may represent a novel 
pharmacological target in the treatment of liver lesions observed 
in chronic hepatitis C.
(2) Farnesoid X receptor (FXR)
The bile acid receptors were found to play a role in bile 
acid-mediated promotion of HCV replication.
100 These data 
suggest a novel mechanism for bile acid-mediated gene 
regulation at virus and host levels. Importantly, these data may 
contribute to the finding of better regimens for the treatment of 
chronic HCV infections by including agents altering the bile 
acid-mediated FXR pathway.
100
(3) Estrogen receptor (ESR)
ESR belongs to the steroid hormone receptor family of the 
nuclear receptor super family. There are two different forms of 
the estrogen receptor, usually referred to as α and β, each 
encoded by a separate gene.
101 The novel role of ESR α in 
regulation of HCV replication has been recently reported.
102 
Tamoxifen and other anti-estrogens suppress genome replication, 
as part of ESR resides on the endoplasmic reticulum and interacts 
with HCV RNA polymerase NS5B, so ESR is suggested to serve 
as a potential novel target for anti-HCV therapies.
102
4) Other
Nitazoxanide
Nitazoxanide is an oral prodrug of a thiazolide (tizoxanide), 
and was approved for the treatment of protozoal infections.
103 In 
addition to having antiprotozoal and antibacterial activity, 
nitazoxanide coincidently was discovered to inhibit HCV 
replication
104 through a recently identified host-mediated 
mechanism of action. Recent studies suggest that nitazoxanide 
and other thiazolides selectively induce PKR phosphorylation, 
which leads to increased cell concentration of phosphorylated 
eIF2, a naturally occurring antiviral intracellular protein.
105 This 
mechanism of action is only triggered when a cell is infected 
with HCV while nitazoxanide has no effect in uninfected cells, 
which provides a possible explanation for its very low rate of 
toxicity. Furthermore, nitazoxanide does not appear to induce 
antiviral resistance, based on an attempt to produce a resistance 
to nitazoxanide and tizoxanide in HCV replicon-containing cell 
lines.
106 The combination of nitazoxanide, peginterferon α-2a, 
and ribavirin increased the percentage of patients with rapid and 
sustained virologic responses, compared with patients given 
peginterferon plus ribavirin, without an increase in adverse 
events.
107 Nitazoxanide, a novel protein kinase inducer, has the 
potential not only to increase the SVR rate but also potentially to 
shorten the duration of therapy.
CONCLUSIONS
The knowledge acquired regarding the HCV life cycle during 
the last decade has been enormous and has lead to multiple new 
anti-HCV therapies under investigation. One anticipates that 
these oral STAT-C drugs will initially be added to current 
PEG-RBV therapy, leading to improved response rates and 
shorter duration of therapy. Future trials will need to evaluate the 
use of ‘‘cocktails’’ of oral agents to see if viral resistance can be 
minimized (similar to HIV and HBV). This may potentially be 
achieved either by a combination of two or more specific 
inhibitors with non-overlapping resistance profiles such as 
protease inhibitors with nucleoside and/or non-nucleoside 
inhibitors or the combination of HCV specific inhibitors with 
non-HCV specific inhibitors such as cyclophilin inhibitors. In 
the meantime, we have developed improved strategies for 
maximizing response rates with current therapy and look to use 
individual viral kinetic responses to tailor treatment duration.
Acknowledgements
None of the authors have any conflict of interest for this manuscript. 
REFERENCES
1. Marcellin P, Boyer N. Transition of care between paediatric and adult 
gastroenterology. Chronic viral hepatitis. Best Pract Res Clin 
Gastroenterol 2003;17:259-275.274  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
2. Bartenschlager R, Lohmann V. Replication of the hepatitis C virus. 
Baillieres Best Pract Res Clin Gastroenterol 2000;14:241-254. 
3. Appel N, Schaller T, Penin F, Bartenschlager R. From structure to 
function: new insights into hepatitis C virus RNA replication. J Biol 
Chem 2006;281:9833-9936.
4. Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C 
virus (HCV): 2006 update. Int J Med Sci 2006;3:29-34.
5. Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. 
Clin Liver Dis 2008 ;12: 675-692, x.
6. Zeuzem S, Sulkowski M, Lawitz E, Rustgi V, Lurie Y, Grigorescu M, et 
al. Efficacy and safety of albinterferon alfa-2b in combination with 
ribavirin in treatment-naive, chronic hepatitis C genotype 1 (CHCG1) 
patients [Abstract]. J Hepatol 2009;50S:S377.
7. Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R, Rodriguez- 
Torres M, et al. Efficacy and safety results od albinterferon alfa-2b in 
combination with ribavirin in interferon alfa treatment naive patients 
with genotype 2 or 3 chronic hepatitis C [Abstract]. J Hepatol 
2009;50S:S378.
8. Lawitz E, Younossi ZM, Shiffman M, Gordon S, Ghalib R, Long W, et 
al. Randomized trial comparing systemic and local reactions to 
controlled-release interferon alfa2b and pegylated - interferon alfa2b in 
hepatitis C patients who failed prior treatment [Abstract]. J Hepatol 
2009;50S:S231.
9. Shiffman M, Lawitz E, Zaman A, Vierling J, Yoffe B, Freeman J, et al. 
Peg-IFN-l: Antiviral activity and safety profile in a 4-week phase 1b 
study in relapsed genotype 1 hepatitis C infection [Abstract]. J Hepatol 
2009;50S:S237.
10. Fukushi S, Kurihara C, Ishiyama N, Hoshino FB, Oya A, Katayama K. 
The sequence element of the internal ribosome entry site and a 
25-kilodalton cellular protein contribute to efficient internal initiation 
of translation of hepatitis C virus RNA. J Virol 1997;71:1662-1666.
11. McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ. et al. 
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), 
administered to chronic hepatitis C patients. J Hepatol 2006;44:88-96.
12. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication 
from genome to function. Nature 2005;436:933-938.
13. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural 
protein 3 of the hepatitis C virus encodes a serine-type proteinase 
required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 
1993;67:3835-3844.
14. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C 
virus-encoded enzymatic activities and conserved RNA elements in the 
3' nontranslated region are essential for virus replication in vivo. J Virol 
2000;74:2046-2051.
15. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM. Regulation of 
interferon regulatory factor-3 by the hepatitis C virus serine protease. 
Science 2003;300:1145-1148.
16. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. 
Immune evasion by hepatitis C virus NS3/4A mediated protease- 
mediated cleavage of the toll like receptor 3 adaptor protein TRIF. Proc 
Natl Acad Sci USA 2005;102:2992-2997.
17. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. 
Telaprevir and peginterferon with or without ribavirin for chronic HCV 
infection. N Engl J Med 2009;360:1839-1850.
18. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, 
Kauffman R, et al. Telaprevir with peginterferon and ribavirin for 
chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
19. Manns M, Muir A, Adda N, Jacobson I, Afdhal N, Heathcote J, et al. 
Telaprevir in hepatitis C genotype-1-infected patients with prior 
non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b 
and ribavirin therapy: SVR results of the PROVE3 study [Abstract]. J 
Hepatol 2009;50S:S379.
20. Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, et 
al . SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 
protease, suppresses polyprotein maturation and enhances the antiviral 
activity of alpha interferon in replicon cells. Antimicrob Agents 
Chemother 2006;50:1013-1020.
21. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. 
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated 
interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 
2007;132:1270-1278.
22. Susser S, Welker MW, Zettler M, Wohnsland A, Hughes E, Ralston R, et 
al. Clonal analysis of mutations selected in the HCV NS3 protease 
domain of genotype 1 non-responders treated with boceprevir [Abstract]. 
J Hepatol 2008;48(S2):S29.
23. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. HCV 
SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir 
plus peginterferon TM (peginterferon alfa-2b)/ribavirin in treatment- 
naive subjects with genotype-1 chronic hepatitis C[Abstract]. J Hepatol 
2009;50S:4.
24. Forestier N, Larrey D, Marcellin P, Benhamou Y, Guyader D, Bradford 
W, et al. Antiviral activity and safety of ITMN-191 in combination with 
peginterferon alfa-2a and ribavirin in patients with chronic hepatitis 
C virus [Abstract]. J Hepatol 2009;50S:35.
25. Reesink H, Bergmann J, de Bruijne J, Weegink C, Van Lier J, Van Vliet 
A, et al. Safety and antiviral activity of SCH 900518 administered as 
monotherapy and in combination with peginterferon alfa-2b to naive 
and treatment-experienced HCV-1 infected patients [Abstract]. J 
Hepatol 2009;50S:S35-S36.
26. Manns M, Reesink H, Moreno C, Berg T, Benhamou Y,  Horsmans Y, et 
al. OPERA-1 trial: Interim analysis of safety and antiviral activity of 
TMC435 in treatment-naive genotype 1 HCV patients [Abstract]. J 
Hepatol 2009;50S:S7.
27. Kukolj G BY, Manns MP, Bourliere M, Pol S, Schuchmann M, et al. BI 
201335, a potent HCV NS3 protease inhibitor in treatment naive and 
-experienced chronic HCV genotype infection: Genotypic and phenotypic 
analysis of the NS3 protease domain. J Hepatol. 2009;50S:347.
28. Michael P. Manns, Marc Bourliere, Yves Benhamou, Stanislas Pol, 
Maurizio Bonacini, Thomas Berg, et al. Safety and antiviral activity of 
BI201335, a new HCV NS protease inhibitor, in treatment naive patients 
with chronic hepatitis C genotype 1 infection given as monotherapy and 
in combination with peginterferon alfa 2a (P) and ribavirin(R) [Abstract]. 
Hepatology 2008;48:1133.
29. Michael P. Manns, Marc Bourliere, Yves Benhamou, Marcus Schu-
chmann, Dieter Haussinger, Stanislas Pol, et al. Safety and antiviral 
activity of BI201335, a new HCV NS3 protease inhibitor, in combination 
therapy with peginterferon alfa 2a (P) and ribavirin (R) for 28 days in 
P+R treatment experienced patients with chronic hepatitis C genotype 1 
infection [Abstract]. Hepatology 2008;48:1151.
30. Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Wiedmann 
R, et al. MK-7009 significantly improves rapid viral response (RVR) in 
combination with pegylated interferon alfa-2a and ribavirin in patients 
with chronic hepatitis C (CHC) genotype 1 infection [Abstract]. J 
Hepatol 2009;50S:S384.
31. Manns MP, Foster Gr, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. 
The way forward in HCV treatment-finding the right path. Nat Rev 
Drug Discov 2007;6:991-1000.
32. Afdhal N, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, 
Lawitz E, et al. Valopicitabine (NM283), alone or with peg-interferon, 
compared to peg interferon/ribavirin (PEGIFN/RBV) retreatment in 
patients with HCV-1 infection and prior non-response to PEG-
IFN/RBV: one-year results [abstract]. J Hepatol 2007;46(S1):S5.
33. Valopicitabine development program placed on clinical hold in the 
United States [press release]. Cambridge (MA): Idenix Pharmaceuti-Jae Young Jang, et al. New treatments for chronic hepatitis C  275
cals Inc; 2007.
34. Nelson D, Pockros PJ, Godofsky E, Rodriguez-Torres M, Everson G, 
Fried M, et al. High end-of-trearment response (84%) after 4 weeks of 
R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a 
further 44 weeks of peginterferon alfa-2a and ribavirin [abstract]. J 
Hepatol 2008;48(S2):S371.
35. Pockros P, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, 
Fried MW, et al. High relapse rate seen at week 72 for patients treated 
with R1626 combination therapy. Hepatology 2008;48:1349-1350.
36. Reddy R, Rodriguez-Torres M, Gane E, Richard Robson, Jacob 
Lalezari, Gregory T. Everson, et al. Antiviral activity, pharmacokine-
tics, safety and tolerability of R7128, a novel nucleoside HCV RNA 
polymerase inhibitor, following multiple, ascending, oral doses in 
patients with HCV genotype 1 infection who have failed prior interferon 
therapy [abstract]. Hepatology 2007;46:862A.
37. Maribel Rodriguez-Torres, Jay Lalezari, Edward J. Gane, Edwin 
DeJesus, David R. Nelson, Gregory T. Everson, et al. Potent antiviral 
response to the HCV nucleoside polymerase inhibitor R7128 for 28 
days with Peg-IFN and ribavirin: subanalysis by race/ethnicity, eight 
and HCV genotype [abstract]. Hepatology 2008;48:1160A.
38. Edward J. Gane, Maribel Rodriguez-Torres, David R. Nelson, Ira M. 
Jacobson, John G. McHutchison, Lennox Jeffers, et al. Antiviral 
activity of the HCV nucleoside polymerase inhibitor R7128 in HCV 
genotype 2 and 3 prior non-responders; interim results of R7128 1500 
mg BID with PEG-IFN and ribavirin for 28 days [abstract]. Hepatology 
2008;48:1024A.
39. Pharmasset and Roche obtain FDA consent to start a phase 2b study 
with R7128 in treatment naive HCV patients [press release]. Princeton 
(NJ): Pharmasset Inc; 2009.
40. Cretton-Scott E, Perigaud C, Peyrottes S, Licklider L, Camire M, 
Larsson M, et al. In vitro antiviral activity and pharmacology of 
IDX184, a novel and potent inhibitor of HCV replication [abstract]. J 
Hepatol 2008;48(S2):S220.
41. Accessed from Idenix website, Available at: www.indenix.com. Accessed 
February. 2009;14.
42. Carrol SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, 
et al. Robust antiviral efficacy upon administration of a nucleoside 
analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents 
Chemother 2009;53:926-934.
43. Villano S, RD, Harper D, Speth J, Chandra P, Shaw D, et al. Antiviral 
activity of the non-nucleoside polymerase inhibitor, HCV-796, in 
combination with pegylated interferon alfa-2b in treatment-naive 
patients with chronic HCV [abstract]. J Hepatol 2007;46(S1):S24.
44. Jacobson I, PP, Lalezari J, Lawitz E, Rodriguez-Torres M, DeJesus E, et 
al. Antiviral activity of filibuvir in combination with pegylated 
interferon alfa-2a and ribavirin for 28 days in treatment naive patients 
chronically infected with HCV genotype 1. J Hepatol. 2009;50S:382.
45. Lawitz E, Cooper C, Rodriguez-Torres M, Ghalib R, Lalonde R, Sheikh 
A, et al. Safety, tolerability and antiviral activity of VCH-916, a novel 
non-nucleoside HCV polymerase inhibitor in patients with chronic 
HCV genotype 1 infection. J Hepatol 2009;50S:S37.
46. Nicolas O, Boivin I, Berneche-D'Amours A, Fex P, Denis F, Selliah S, et 
al. Genotypic and phenotypic analysis of HCV NS5B variants selected 
from patients treated with VCH-916 [Abstract]. J Hepatol 2009; 
50S:S349.
47.  Lawitz E, Rodriguez-Torres M, DeMicco M, Nguyen T, Godofsky E, 
Appleman J, et al. Antiviral activity of ANA598, a potent non-nucleoside 
polymerase inhibitor, in chronic hepatitis C patients [Abstract]. J Hepatol 
2009;50S:S384.
48. Cooper C, Larouche R, Bourgault B, Chauret N, Proulx L. Safety, 
tolerability and pharmacokinetics of the HCV polymerase inhibitor 
VCH-222 following single dose administration in healthy volunteers 
and antiviral activity in HCV-infected individuals [Abstract]. J Hepatol 
2009;50S:S342.
49. Brainard D, Wright DH, Sneddon K, Cummings C, Sun P, Valentine 
J, et al. Safety, tolerability, and pharmacokinetics after single and 
multiple doses of MK3281 in healthy subjects [Abstract]. J Hepatol 
2009;50S:S341.
50. Gane EJ, Roberts SK,  Stedman C, Angus PW, Ritchie B, Elston R, et al. 
First in-man demonstration of potent antiviral activity with a nucleoside 
polymerase (R7128) and protease (R7227/ITMN- 191) inhibitor 
combination in HCV: Safety, pharmacokinetics, and virologic results 
from INFORM-1 [Abstract]. J Hepatol 2009;50S:S380
51. Aizaki H, Morikawo K, Fukasawa M, Hara H, Inoue Y, Tani H, et al. 
Critical role of virion-associated cholesterol and sphingolipid in 
hepatitis C virus infection. J Virol 2008;82:5715-5724.
52. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere 
I, Reiser H, et al. Anti-CD81 antibodies can prevent a hepatitis C virus 
infection in vivo. Hepatology 2008;48:1761-1768.
53. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, 
Wychowski C, et al. Hepatitis C virus entry depends on clathrin- 
mediated endocytosis. J Virol 2006;80:6964-6972.
54. Codran A, Royer C, Jaeck D, Bastien-Valle M, Baumert TF, Kieny MP, 
et al. Entry of hepatitis C virus pseudotypes into primary human 
hepatocytes by clathrin-dependent endocytosis. J Gen Virol 2006;87: 
2583-2593.
55. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. 
Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
56. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, 
et al. The human scavenger receptor class B type I is a novel candidate 
receptor for the hepatitis C virus. EMBO J 2002;21:5017-5025.
57. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus 
and other flaviviridae viruses enter cells via low density lipoprotein 
receptor. Proc Natl Acad Sci USA 1999;96:12766-12771.
58. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. 
Claudin-1 is a hepatitis C virus co-receptor required for a late step in 
entry. Nature 2007;446:801-805.
59. Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, Abrignani S, et 
al. CD81 extracellular domain 3D structure: insight into the tetraspanin 
superfamily structural motifs. EMBO J 2001;20:12-18.
60. Liu C, D Coco, Dong HJ, Eksioglu E, Zhu H, Ostrov D. Novel antiviral 
small molecules that block hepatitis C virus cellular entry through the 
CD81 receptor. 14th International Symposium on Hepatitis C and 
Related Viruses; 2007;september 9-13; Glasgow, UK.
61. Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, 
Diepolder HM, et al. Scavenger receptor class B is required for hepatitis 
C virus uptake and cross-presentation by human dendritic cells. J Virol 
2008;82:3466-3479.
62. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, et al. An 
interplay between hypervariable region 1 of the hepatitis C virus E2 
glycoprotein, the scavenger receptor BI, and high-density lipoprotein 
promotes both enhancement of infection and protection against 
neutralizing antibodies. J Virol 2005;79:8217-8229.
63. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot 
PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing 
antibodies by stimulating cell entry via activation of the scavenger 
receptor BI. J Biol Chem 2006;281:18285-18295.
64. Koike K. Hepatitis C as a metabolic disease: Implication for the 
pathogenesis of NASH. Hepatol Res 2005;33:145-150.
65. Jarmay K, Karacsony G, Nagy A, Schaff Z. Changes in lipid metabolism 
in chronic hepatitis C. World J Gastroenterol 2005;11:6422-6428.
66. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association 
of diabetes and hepatitis C infection: epidemiologic evidence and 
pathophysiologic insights. Curr Diab Rep 2004;4:194-198.276  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
67. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G. et al. 
Reduced bone mineral density and altered bone turnover markers in 
patients with non-cirrhotic chronic hepatitis B or C infection. World J 
Gastroenterol 2005;11:1843-1847.
68. Nanda KS, Ryan EJ, Murray BF, Brady JJ, McKenna MJ, Nolan N, et al. 
Effect of chronic hepatitis C virus infection on bone disease in 
postmenopausal women. Clin Gastroenterol Hepatol 2009;7:894-899.
69. Torres DM, Harrison SA. HCV replication and statin pleotropism: an 
adjuvant treatment panacea? Am J Gastroenterol 2008;103:1390-1392.
70. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, et al. Hepatitis C 
virus production by human hepatocytes dependent on assembly and 
secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 
2007;104:5848-5853.
71. Burnett JR. Drug evaluation: ISIS-301012, an antisense oligonuc-
leotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther. 
2006;8:461-467.
72. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis 
A, et al. Inhibition of microsomal triglyceride transfer protein in 
familial hypercholesterolemia. N Engl J Med 2007;356:148-156.
73. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, et 
al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and 
triglycerides in experimental animals and in humans. J Lipid Res 2003; 
44:1887-1901.
74. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, et 
al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited 
by the grapefruit flavonoid naringenin. Hepatology 2008;47: 
1437-1445.
75. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. 
Cyclophilin B is a functional regulator of hepatitis C virus RNA 
polymerase. Mol Cell 2005;19:111-122.
76. Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wier-
cinska-Drapalo A, et al. The cyclophilin inhibitor Debio-025 shows 
potent anti-hepatitis C effect in patients coinfected with hepatitis C and 
human immunodeficiency virus. Hepatology 2008;47:817-826.
77. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 
2006;12:7075-7080.
78. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T; LIDO 
Study Group. Fibrogenic impact of high serum glucose in chronic 
hepatitis C. J Hepatol 2003;39:1049-1055.
79. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago 
M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained 
response rate to peginterferon plus ribavirin in chronic hepatitis C 
patients. Gastroenterology 2005;128:636-641.
80. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha 
treatment in hepatitis C virus. Hepatology 2004;39:880-890.
81. Mbow ML, Sarisky RT. What is disrupting IFN-alpha's antiviral 
activity? Trends Biotechnol 2004;22:395-399.
82. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, I de T, et al. 
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 
through up-regulation of suppressor of cytokine signaling 3. Am J 
Pathol 2004;165:1499-1508.
83. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, et 
al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates 
insulin receptor substrate 1 through genotype-specific mechanisms. 
Hepatology 2007;45:1164-1171.
84. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, 
Clouston AD, et al. Non-response to antiviral therapy is associated with 
obesity and increased hepatic expression of suppressor of cytokine 
signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 
1. Gut 2006;55:529-535.
85. Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano 
L, et al. Virus-induced over-expression of protein phosphatase 2A 
inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008;49: 
429-440.
86. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. 
Tumor necrosis factor-alpha-induced insulin resistance may mediate 
the hepatitis C virus-diabetes association. Am J Gastroenterol 2003;98: 
2751-2756.
87. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et 
al. Hepatitis C virus infection and diabetes: direct involvement of the 
virus in the development of insulin resistance. Gastroenterology 
2004;126:840-848.
88. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections 
and anti-tumor necrosis factor-alpha therapy: guidelines for clinical 
approach. J Gastroenterol Hepatol 2006;21:1366-1371.
89. Romero-Gomez M, Diego M, Andrade RJ, Calleja JL, Salmeron J, 
Fernandez-Rodriguez CM, et al. Metformin with peginterferon alfa-2a 
and ribavirin in the treatment of naïve genotype 1 chronic hepatitis C 
patients with insulin resistance (TRIC-1): final results of a randomized 
and double blinded trial [abstract]. Hepatology 2008;48:380A.
90. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun 
A, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein 
metabolism in patients with type 2 diabetes mellitus. J Clin Invest 
2005;115:1323-1332.
91. Negro F. Peroxisome proliferator-activated receptors and hepatitis C 
virus-induced insulin resistance. PPAR Res 2009;2009:483485.
92. Frederiksen KS, Wulf EM, Wassermann K, Sauerberg P, Fleckner J. 
Identification of hepatic transcriptional changes in insulin-resistant rats 
treated with peroxisome proliferator activated receptor-alpha agonists. J 
Mol Endocrinol 2003;30:317-329.
93. Jay MA Ren J . Peroxisome proliferator-activated receptor (PPAR) in 
metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 
2007;3:33-39.
94. Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF. Distinct 
mechanisms of glucose lowering by specific agonists for peroxisomal 
proliferator activated receptor gamma and retinoic acid X receptors. J 
Biol Chem 2005;280:38317-38327.
95. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma 
and PPARdelta negatively regulate specific subsets of lipopolysaccharide 
and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A 
2003;100:6712-6717.
96. Henson P. Suppression of macrophage inflammatory responses by 
PPARs. Proc Natl Acad Sci USA. 2003;100:6295-6296.
97. de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, 
Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor- alpha 
and -gamma mRNA levels are reduced in chronic hepatitis C with 
steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006;23: 
107-114.
98. Takada N, Sanda T, Okamoto H, Yang JP, Asamitsu K, Sarol L, et al. 
RelA-associated inhibitor blocks transcription of human immu-
nodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions. J 
Virol 2002;76:8019-8030.
99. Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, et al. 
Effects of bezafibrate in patients with chronic hepatitis C virus 
infection: combination with interferon and ribavirin. J Viral Hepat 
2006;13:441-448.
100. Chang KO, George DW. Bile acids promote the expression of hepatitis 
C virus in replicon-harboring cells. J Virol 2007;81:9633-9640.
101. Li X, Huang J, Yi P, Bambara RA, Hilf R, Muyan M. Single-chain 
estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer 
emulates functions of the ERalpha dimer in genomic estrogen 
signaling pathways. Mol Cell Biol 2004;24:7681-7694.
102. Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K. 
Anti-hepatitis C virus activity of tamoxifen reveals the functional Jae Young Jang, et al. New treatments for chronic hepatitis C  277
association of estrogen receptor with viral RNA polymerase NS5B. J 
Biol Chem 2007;282:32765-32772.
103. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the 
treatment of gastrointestinal infections. Drugs 2007;67:1947-1967.
104. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, et 
al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors 
of hepatitis B virus and hepatitis C virus replication. Antiviral Res 
2008;77:56-63.
105. Elazar M LM, McKenna S, Liu P, Gehrig EA, Elfert A, et al. 
Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation 
[abstract]. Hepatology. 2008;48:1151A.
106. Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for 
hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob 
Agents Chemother 2008;52:4069-4071.
107. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic 
response in chronic hepatitis C genotype 4 treated with nitazoxanide, 
peginterferon, and ribavirin. Gastroenterology 2009;136:856-862.